Cipla Files Post-Grant Opposition Against GSK’s Tykerb Patent
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian drug maker contends lapatanib is simply a combination of two compounds invented before 1995.
You may also be interested in...
Cipla Challenges Delhi Court’s Decision Restraining India’s Drug Controller From Granting Marketing Nod For Sorafenib
MUMBAI - Indian drug companies are mounting a strong opposition against ex-parte judgements passed by Indian courts restraining the Drug Controller General of India from processing marketing approvals of their drugs
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.